Myriad Genetics, Inc. (MYGN) reported adjusted earnings of 5 cents per share in the second quarter of 2024 compared to the Zacks Consensus Estimate of a loss of 1 cent per share. The reported figure also compares to a loss of 8 cents per share in the year-ago quarter.The quarter’s adjustments exclude amortization expenses from acquired intangible assets, equity compensations and real estate optimization, among others.RevenuesTotal revenues rose 15.3% year over year to $211.5 million in the quarter under rev ...